BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $20.60 Average PT from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.60.

A number of research analysts have recently commented on BCRX shares. Wedbush cut their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Citizens Jmp increased their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Wall Street Zen raised BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st.

Institutional Trading of BioCryst Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its holdings in shares of BioCryst Pharmaceuticals by 231.6% in the 1st quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after buying an additional 3,556,208 shares during the period. Pacer Advisors Inc. bought a new position in shares of BioCryst Pharmaceuticals during the 1st quarter worth $14,880,000. Perceptive Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after buying an additional 4,271,504 shares during the period. Wedge Capital Management L L P NC purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at $3,808,000. Finally, NFJ Investment Group LLC bought a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at about $2,788,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 1.5%

BCRX stock opened at $9.83 on Friday. The stock has a market cap of $2.51 billion, a PE ratio of -6.55 and a beta of 0.56. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.22. The company has a 50-day moving average price of $9.66 and a 200 day moving average price of $9.00.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm’s revenue for the quarter was up 33.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.15 EPS. Sell-side analysts forecast that BioCryst Pharmaceuticals will post -2.25 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.